Neurosense Therapeutics is trading at $2.51, down -5.82% in after-hours trading, with no verified company-specific catalyst linked to the decline.
- Neurosense Therapeutics filed a U.S. patent application on October 19 covering potential PrimeC use for traumatic brain injury.
- The filing is an application, not an issued patent, and available coverage does not connect it to the decline.
- Broader market context is mixed and does not clearly explain the stock’s move.